gbfi

Strong R&D

Reagena is committed to development, production and marketing of innovative diagnostics products.

Proven examples of these are the proprietary immuno-chromatography technology together with ReaScan reader and the point-of-care and the EIA tests for acute Hantavirus infections and immunity.

The easy-to-use rapid tests of Reagena enable excellent sensitivity and specificity, and combine the advantages of traditional laboratory tests and point-of-care testing for laboratory clinicians.

The most recent (autumn 2017) addition to the Reagena zoonosis portfolio was a new diagnostic tool for the rapid determination of chemokine CXCL13 - learn more on ReaScan CXCL13.

Reagena professionals work in close collaboration with leading international universities and research institutes in several countries.

Fotolia_39241220_.jpg